Regular adult aspirin use decreases the risk of non-small cell lung cancer among women

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 1, 2008, Pages 148-157

  Van Dyke, Alison L ^a   Cote, Michele L ^a   Prysak, Geoffrey ^a   Claeys, Gina B ^a   Wenzlaff, Angie S ^a   Schwartz, Ann G ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO;

ADULT; AGED; ANAMNESIS; ARTICLE; BODY MASS; CALCULATION; CASE CONTROL STUDY; CAUCASIAN; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; ETHNIC DIFFERENCE; FEMALE; HUMAN; INFORMATION PROCESSING; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SMOKING; STATISTICAL SIGNIFICANCE;

ACETAMINOPHEN; ADENOCARCINOMA; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BODY MASS INDEX; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; ODDS RATIO; RISK ASSESSMENT; SEER PROGRAM; UNITED STATES;

EID: 38849172992     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0517     Document Type: Article

References (46)

1. Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004. Bethesda (MD): National Cancer Institute; 2007. Available from: http://seer.cancer.gov/csr/1975_2004/ based on November 2006 SEER data submission.
2. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005;97:1407-27.
3. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-4.
4. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
5. Hasturk S, Kemp B, Kalapurakal SK, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and non-small cell lung carcinoma. Cancer 2002;94:1023-31.
6. Fang HY, Lin TS, Lin JP, et al. Cyclooxygenase-2 in human non-small cell lung cancer. Eur J Surg Oncol 2003;29:171-7.
7. Ermert L, Dierkes C, Ermert M. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin Cancer Res 2003;9:1604-10.
8. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-5.
9. Hosomi Y, Yokose T, Hirose Y, et al. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 2000;30:73-81.
10. Brabender J, Park J, Metzger R, et al. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg 2002;235:440-3.
11. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861-7.
12. Yuan A, Yu CJ, Shun CT, et al. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer 2005;115:545-55.
13. Campa D, Zienolddiny S, Maggini V, et al. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 2004;25:229-35.
14. Campa D, Zienolddiny S, Maggini V, et al. Corrigendum: Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 2005;26:1157.
15. Hu Z, Miao X, Ma H, et al. A common polymorphism in the 3′UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population. Lung Cancer 2005;48:11-7.
16. Park JM, Choi JE, Chae MH, et al. Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study. BMC Cancer 2006;6:70.
17. Sorensen M, Autrup H, Tjonneland A, et al. A genetic polymorphism in prostaglandin synthase 2 (8473, T->C) and the risk of lung cancer. Cancer Lett 2005;226:49-54.
18. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:47-55.
19. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-46.
20. Paganini-Hill A, Chao A, Ross RK, et al. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989;299:1247-50.
21. Friis S, Sorensen HT, McLaughlin JK, et al. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 2003;88:684-8.
22. Holick CN, Michaud DS, Leitzmann MF, et al. Aspirin use and lung cancer in men. Br J Cancer 2003;89:1705-8.
23. Jacobs EJ, Thun MJ, Bain EB, et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007;99:608-15.
24. Hayes JH, Anderson KE, Folsom AR. Association between nonsteroidal anti-inflammatory drug use and the incidence of lung cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 2006;15:2226-31.
25. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, et al. Aspirin and lung cancer in women. Br J Cancer 2002;87:49-53.
26. Moysich KB, Menezes RJ, Ronsani A, et al. Regular aspirin use and lung cancer risk. BMC Cancer 2002;2:31.
27. Hernandez-Diaz S, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of lung cancer. Int J Cancer 2007;120:1565-72.
28. Muscat JE, Chen SQ, Richie JP, Jr., et al. Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs. Cancer 2003;97:1732-6.
29. Harris RE, Beebe-Donk J, Alshafie GA. Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study. Int J Biol Sci 2007;3:328-34.
30. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988;296:313-6.
31. Thun MJ, Namboodiri MM, Calle EE, et al. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-7.
32. Ratnasinghe LD, Graubard BI, Kahle L, et al. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 2004;24:3177-84.
33. Harris RE, Beebe-Donk J, Doss H, et al. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-sleective COX-2 blockade. Oncol Rep 2005;13:559-83.
34. Harris RE, Beebe-Donk J, Schuller HM. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep 2002;9:693-5.
35. Botting RM. Mechanism of action of acetaminophen: is there a cyclooxygenase-3? Clin Infect Dis 2000;31:S202-10.
36. Chandrasekharan NV, Dai H, Lamar Turepu Roos K, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci 2002;99:13926-31.
37. Kis B, Snipes JA, Isse T, et al. Putative cyclooxygenase-3 expression in rat brain cells. J Cereb Blood Flow Metab 2003;23:1287-92.
38. Berenbaum F. COX-3: Fact or fancy? Joint Bone Spine 2004;71:451-3.
39. Kis B, Snipes JA, Simandle SA, et al. Acetaminophen-sensitive prostaglandin production in rat cerebral endothelial cells. Am J Physiol Integr Comp Physiol 2005;288:R897-902.
40. Kis B, Snipes JA, Busija DW. Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties. J Pharmacol Exp Ther 2005;315:1-7.
41. Khuder SA, Herial NA, Mutgi AB, et al. Nonsteroidal antiinflammatory drug use and lung cancer: a metaanalysis. Chest 2005;127:748-54.
42. Sorensen HT, Friis S, Norgard B, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003;88:1687-92.
43. Skriver MV, Norgaard M, Poulsen AH, et al. Use of nonaspirin NSAIDs and risk of lung cancer. Int J Cancer 2005;117:873-6.
44. Rosenberg L. Nonsteroidal anti-inflammatory drugs and cancer. Prev Med 1995;24:107-9.
45. Langman MJ, Cheng KK, Gilman EA, et al. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000;320:1642-6.
46. Wall RJ, Shyr Y, Smalley W. Nonsteroidal anti-inflammatory drugs and lung cancer risk: a population-based case control study. J Thoracic Oncol 2007;2:109-14.